Chronologie
August 2001 Ansell verkauft Anteile an Ambri an Optecom
August 2001 Optecom benennt sich in Ambri Ltd. um
Dez. 2002 Dr John Eady Ambri's non-executive director geht zur Konkurrenz
Gradipore.com wo er allerdings auch nicht lange bleibt aufgrund des
katstrophalen Zustandes des Aktienkurses
März 2003 Joe Shaw President und CEO von Ambri geht nach Amerika zu AAGI
(www.ausamericangroup.com/aboutus.php) und trifft
dort Andrew Mc. Crea wieder, ex. Director Corporate Strategy und Börsenprofi
Dez. 2003 Ambri von Ansell-Mutter bereits fast abgeschrieben
Wo kommen denn die 20 Mio. bei Ambri her ? (20 Mio. bank bill = Wechsel?)
Im Detail :
2001 Ansell verkauft Anteil an Ambri an Optecom
Most of the major problems which have dragged the Company down in recent year are now either behind it, or close to resolution. Ambri's biosensor technology business was sold to Optecom Limited to reduce cash commitments going forward.
We believe that the prospects of successful commercialsisation of the technology are very good, but continuing to bear the full risks of the ongoing R&D was not appropriate for the company.
Dezember 2002
Gradipore strengthens board
Australia's Gradipore Ltd has appointed Dr John Eady as non-executive director.
Dr Eady is currently chairman of Ambri Ltd, a newly-listed biotechnology company which, as with Gradipore, is in the process of commercializing its intellectual property.
Recently, he has also advised a US-based company on revitalising its management and to achieve best practice.
During his career, Dr Eady spent more than 26 years with CRA and its subsidiaries. He is an experienced director, having held directorships with the Australia Industry Research and Development Board, Comalco Aluminium, Comalco Bell Bay Pty Ltd, Southern Aluminium Ltd, the AIDC, and Comalco and Rio Tinto, Japan.
Gradipore is a biotechnology company that researches, develops, manufactures and markets haematological and separation technologies principally to provide increased efficiency for research and development for the life science market throughout the world.
Intention to convene a General Meeting of Shareholders
30 May 2003
Gradipore Limited has received a letter from Mr John Manusu, a director of the company, advising that it is his intention to convene a general meeting of the company on 30 June 2003. A draft Notice of General Meeting, which accompanied the letter, includes resolutions to appoint 2 new directors and remove 4 current serving directors.
The letter and Notice advise that the following are to be proposed for election as directors:
· Mr John Fernandez
· Mr Gregory Desmond Fagan
and the following to be removed:
· Mr Jeremy Davis
· Dr John Eady
· Mr Robert Lieb
· Mr Leslie Webb
März 2003 Joe Shaw geht nach Amerika zu AAG www.ausamericangroup.com
und trifft dort Andrew Mc. Crea wieder !
Auszug aus Mc.Creas Lebenslauf :
Currently, a principal of Aus-American Group Inc, an international consulting firm. Previously, Mr McCrea was Director Corporate Strategy, Ambri Limited a biotechnology company listed on the Australian Stock Exchange. From 1998-2001, Mr McCrea was CEO of Qpax Inc. in New York, NY a software technology firm until it was acquired by Worldspan Inc. Previously, from 1993-98, Mr McCrea was founder and CEO of Permanent Capital Sdn Bhd – an investment banking group in Kuala Lumpur, Malaysia. Previously, Mr McCrea was a Senior Consultant for Fairgill Investments Pty Ltd – an investment company of members of the Fairfax family in Sydney, Australia. Previous to that, Mr McCrea worked on Wall Street for a division of Citicorp NA investment bank (Citibank) as a Vice President – International division.
Auszug aus Shaws Lebenslauf
From April 1987 Dr. Shaw was Vice President and Head of diagnostics of Quadra Logic Technologies, Inc., a company listed on NASDAQ and the Toronto Stock Exchange. Subsequently Dr. Shaw founded Quantech Ltd. a medical diagnostics biosensor company originally taken public in Italy and subsequently on NASDAQ where it trades today. In July 1999 Dr Shaw was appointed President & CEO of Ambri Limited. He has broad international experience in biotechnology and has extensive experience in Canada, Australia, Italy and the United States as a senior executive in medical corporations
Ende 2003
aus Ansell Finanzreports :
Non Recurring Items
1. A non-cash write-down of US$5.3 million for equipment from the now closed Massillon manufacturing facility. A provision had been formally approved by the Board as part of the 2001 restructure, but not made pending evaluation of alternative uses for this surgical glove manufacturing equipment. However, following successful conversion of examination glove production lines in Colombo, and further additions currently planned, it is now clear that this equipment will not be required.
-5-
2. A further decline in the share price of Ambri Ltd. from A37.5¢ to the market value at 31 December, 2003 of A25¢ a share, resulted in an US$0.7 M non-cash mark down of Ansell’s investment. The book value of this investment now stands at US$1.5 M.
3. There was a US$5.5 million cash gain from a refund of Australian Sales Tax related to a discontinued business.
In addition to the activities of our business units mentioned below,
we continued to make good progress in reducing the cost of operating
our corporate offices, almost halving the cost from the previous year
on a comparable basis.
The total Company result was achieved after a $6.1 million (US$3.6 million)
non-cash write-down to market value at 30 June 2003 of our residual
non-core investment in Ambri Limited.
We have worked hard to develop a new culture that is more entrepreneurial,
analytical and results driven, and we are continuing to concentrate on
improving our existing operating efficiencies and accelerating restructuring
programs in each of the regions – the Americas, Europe and Asia Pacific –
in which we operate.
Ansell’s non-core investment in Ambri Limited, which
resulted from the sale by Ansell in August 2001 of its
former wholly-owned subsidiary, Ambri Pty Limited,
has been written down from the original float price
of $1.11 per share to the 30 June 2003 market price
of $0.375. A non-cash write-off of $6.1 million
(US$3.6 million) in FY2003 reduced the book value
of Ansell’s investment in Ambri Limited to $3.1 million
(US$2.1 million).
Zurück
